journal
preproof
j
u
r
n
l
p
r
e
p
r
f
abstract
sever
acut
respiratori
syndrom
coronaviru
novel
coronaviru
respons
ongo
human
pandem
massiv
intern
effort
underway
develop
diagnost
reagent
vaccin
antivir
drug
bid
slow
spread
diseas
save
live
one
part
intern
effort
involv
research
commun
work
plant
bring
research
world
togeth
commerci
enterpris
order
achiev
rapid
suppli
protein
antigen
antibodi
diagnost
kit
scalabl
product
system
emerg
manufactur
vaccin
antivir
drug
look
way
plant
use
fight
outbreak
potenti
lethal
coronaviru
wuhan
china
decemb
creat
pandem
provok
govern
across
world
introduc
emerg
contain
control
measur
aim
measur
delay
spread
infect
thu
reduc
acut
pressur
hospit
bed
frontlin
medic
staff
resourc
slow
rate
infect
therebi
reduc
total
number
acut
case
one
time
help
prevent
collaps
nation
healthcar
system
tactic
also
give
research
time
develop
effect
test
assay
identifi
carrier
treatment
reduc
sever
symptom
resolv
infect
quickli
vaccin
candid
protect
unexpos
segment
popul
research
work
applic
plant
play
key
role
critic
time
use
knowledg
infrastructur
mean
develop
produc
new
diagnost
therapeut
inde
plant
may
offer
platform
use
manufactur
reagent
scale
timefram
week
compar
month
even
year
cellbas
system
look
three
area
plant
could
make
major
contribut
diagnost
reagent
identifi
infect
recov
individu
vaccin
prevent
infect
antivir
treat
symptom
support
growth
human
pathogen
howev
advantag
gener
persuas
enough
displac
major
product
platform
use
biolog
manufactur
industri
establish
platform
util
bacterium
escherichia
coli
microb
variou
mammalian
cell
line
mainli
due
robust
regulatori
framework
exist
system
histor
industri
invest
correspond
product
technolog
howev
plant
carv
nich
small
number
case
produc
biolog
favor
glycan
configur
taligluceras
alfa
allow
product
massiv
scale
requir
hiv
microbicid
andmost
relev
current
situationwhen
transient
express
system
use
scale
rapidli
meet
sudden
unforeseen
demand
ideal
product
diagnost
reagent
vaccin
candid
antivir
drug
face
rapidli
spread
pandem
diseas
figur
rapid
spread
gener
sudden
huge
demand
diagnost
kit
reveal
critic
shortag
correspond
reagent
mean
produc
two
major
diagnost
assay
requiredon
detect
viru
thu
identifi
infect
popul
potenti
spreader
diseas
one
detect
antibodi
viru
thu
identifi
current
infect
well
convalesc
potenti
immun
popul
assay
detect
viru
fall
two
categori
base
detect
viru
genom
rna
base
detect
viru
protein
rnabas
assay
develop
soon
sequenc
deposit
genbank
ncbi
refer
sequenc
viru
detect
rtpcr
specif
assay
compon
primer
easi
synthes
howev
one
problem
assay
absenc
univers
posit
control
would
allow
standard
across
differ
test
laboratori
group
john
inn
centr
jic
norwich
uk
led
georg
lomonossoff
hadrien
peyret
therefor
develop
diagnost
control
reagent
base
viruslik
particl
vlp
deriv
cowpea
mosaic
viru
cpmv
vlp
structur
parent
viru
lack
nativ
genom
therefor
unabl
replic
use
approach
first
develop
outbreak
foot
mouth
diseas
viru
jic
group
packag
artifici
rna
contain
genom
region
detect
world
health
organ
test
kit
insid
cpmvderiv
vlp
produc
assembl
plant
vlp
thermost
highli
reproduc
scalabl
standard
reagent
use
sourc
posit
control
rna
rtpcr
assay
georg
lomonossoff
hadrien
peyret
person
commun
develop
kit
detect
viru
protein
requir
specif
ligand
usual
achiev
identif
correspond
antibodi
matur
particl
contain
four
structur
protein
known
envelop
e
membran
nucleocapsid
n
spike
protein
protein
import
term
antibodybas
detect
project
surfac
virion
expos
journal
preproof
j
u
r
n
l
p
r
e
p
r
f
receptor
bind
domain
rbd
immun
system
figur
inject
whole
prepar
isol
recombin
proteinrbd
mice
use
gener
hybridoma
clone
proteinrbd
use
screen
phage
antibodi
display
librari
similar
platform
ultim
yield
sequenc
antibodi
high
affin
protein
scaledup
product
antibodi
would
allow
stockpil
kit
viru
detect
use
faster
conveni
format
enzymelink
immunosorb
assay
elisa
later
flow
assay
assay
base
protein
chip
recombin
viru
protein
transient
antibodi
express
plant
provid
rapidli
scalabl
express
platform
ramp
product
short
term
transgen
plant
fulfil
need
longerterm
highvolum
suppli
histori
molecular
farm
kick
public
natur
paper
describ
product
antibodi
tobacco
nicotiana
tabacum
year
ago
remain
product
class
express
often
greatest
divers
term
antibodi
format
express
strategi
host
speciesplatform
product
diagnost
antibodi
plant
therefor
take
advantag
extens
knowledg
knowhow
accumul
ensur
plantderiv
antibodi
stabl
function
produc
high
yield
public
sequenc
also
provid
inform
requir
gener
recombin
viral
protein
diagnost
reagent
avail
protein
allow
immedi
develop
assay
detect
serum
antibodi
convalesc
patient
particularli
antibodi
protein
plant
provid
mean
produc
protein
within
week
massiv
scale
kit
manufactur
stockpil
distribut
test
center
contrast
would
take
month
establish
cell
line
express
reagent
possibl
year
ramp
product
capac
necessari
level
therefor
envisag
scenario
transient
express
system
use
address
press
need
larg
quantiti
reagent
short
term
month
complement
transgen
plant
achiev
even
largerscal
product
longerterm
basi
exampl
former
approach
italian
biotechnolog
compani
diamant
use
tobacco
express
antigen
base
rbd
use
elisa
test
detect
serum
antibodi
convent
approach
vaccin
develop
would
base
inactiv
attenu
strain
approach
take
long
time
produc
suffici
materi
vaccin
mani
disadvantag
side
effect
includ
risk
reacquir
virul
quicker
safer
altern
product
subunit
vaccin
base
individu
protein
could
present
either
individu
antigen
primeboost
schedul
suitabl
adjuv
vlp
multipl
copi
antigen
array
surfac
strategi
current
develop
mean
address
pandem
four
structur
protein
could
potenti
elicit
neutral
antibodi
tcell
respons
howev
research
origin
sarscov
strain
indic
n
protein
unsuit
highli
conserv
among
cov
famili
includ
commonli
encount
form
common
cold
antibodi
rais
n
provid
protect
immun
wherea
e
protein
elicit
weak
protect
respons
unusu
among
coronavirus
protein
proteolyt
cleav
subunit
amino
acid
membranespan
subunit
amino
acid
latter
highli
conserv
among
cov
famili
contrast
show
ident
human
cov
strain
differ
concentr
rbd
facilit
viru
entri
bind
angiotensinconvert
enzym
cell
surfac
block
viral
entri
success
strategi
control
infect
vaccin
candid
origin
sarscov
target
protein
reason
induc
neutral
antibodi
respons
antibodydepend
cellmedi
cytotox
adcc
crosspresent
achiev
protect
cellular
immun
mani
subunit
vaccin
candid
alreadi
produc
plant
includ
sever
season
pandem
strain
influenzaviru
produc
transient
express
tobacco
vaccin
manufactur
within
three
week
receiv
hemagglutinin
neuraminidas
sequenc
produc
use
deconstruct
vector
base
tobacco
mosaic
viru
deliv
agroinfiltr
agrobacterium
tumefacien
basi
technolog
approach
develop
year
ago
mg
protein
produc
per
kg
fresh
leav
least
one
compani
thought
develop
vaccin
base
express
protein
subunit
tobacco
plant
name
kentucki
bioprocess
owensboro
kt
usa
subsidiari
british
american
tobacco
although
detail
publicli
avail
target
like
protein
sequenc
complet
polypeptid
smaller
rbd
within
protein
sarscov
heavili
glycosyl
glycan
mixtur
complex
highmannos
configur
make
necessari
express
recombin
rbd
ntermin
signal
peptid
ensur
protein
secret
endomembran
system
unclear
whether
differ
structur
complex
glycan
human
plant
make
differ
effect
plantbas
vaccin
although
structur
highmannos
glycan
fulli
conserv
across
higher
eukaryot
least
epitop
consist
previou
report
coronaviru
protein
express
plant
ectodomain
swine
transmiss
gastroenter
coronaviru
tgev
express
transgen
arabidopsi
thaliana
line
recombin
antigen
elicit
tgevspecif
antibodi
mice
demonstr
immunogen
coronaviru
antigen
produc
plant
develop
vlp
display
antigen
vaccin
multipl
advantag
particl
taken
effici
antigenpres
cell
due
size
trigger
adapt
immun
system
order
proteinac
structur
recogn
danger
signal
stimul
strong
cellular
humor
respons
vlp
base
plant
virus
provid
addit
layer
safeti
even
nativ
particl
replic
human
produc
massiv
quantiti
molecular
farm
plant
vlp
platform
use
tobacco
plant
product
host
develop
medicago
inc
canada
achiev
import
mileston
produc
million
dose
vaccin
influenza
one
month
part
journal
preproof
darpa
blue
angel
program
medicago
recent
announc
intent
use
platform
rapid
product
vlpbase
vaccin
although
precis
natur
vlp
remain
confidenti
similarli
ibio
bryan
tx
usa
develop
vlpbase
vaccin
tobacco
plant
base
proprietari
fastpharm
system
wherea
viru
subunit
antigen
vlp
design
elicit
immun
respons
pathogen
encount
wild
inject
recombin
antibodi
could
help
slow
infect
give
bodi
time
rais
antibodi
patient
succumb
diseas
strategi
support
recent
find
serum
convalesc
patient
reduc
sever
diseas
symptom
acceler
recoveri
plant
could
therefor
use
produc
antibodi
viru
detect
reagent
also
form
passiv
immunotherapi
blueprint
approach
establish
mapp
biopharmaceut
san
diego
ca
usa
commerci
arm
leafbio
outbreak
zair
ebolaviru
west
africa
compani
manufactur
cocktail
three
neutral
antibodi
known
zmapp
approv
compassion
use
due
lifesav
potenti
lack
altern
larg
dose
mg
per
patient
antibodi
requir
would
mean
transgen
plant
grown
massiv
scale
would
econom
rout
manufactur
product
similarli
potenti
largescal
product
broadlyneutr
hivspecif
antibodi
demonstr
transgen
tobacco
maiz
zea
may
rice
oryza
sativa
german
govern
issu
good
manufactur
practic
gmp
licens
fraunhof
ime
product
tobacco
test
firstinhuman
phase
clinic
trial
similar
model
could
use
neutral
antibodi
furthermor
rice
recent
proven
versatil
mean
produc
along
two
antivir
lectin
see
next
section
could
reduc
cost
preformul
cocktail
activ
ingredi
addit
product
antibodi
neutral
viru
directli
plant
could
also
use
produc
larg
amount
therapeut
antibodi
inhibit
cytokin
storm
follow
infect
mani
sever
fatal
case
two
antibodi
could
repurpos
treatment
sarilumabkevzara
tocilizumabactemra
bind
receptor
indic
treatment
rheumatoid
arthriti
undergo
clinic
trial
antivir
drug
inhibit
viral
replic
cycl
therefor
slow
infect
give
immun
system
time
respond
mani
antivir
drug
small
chemic
entiti
produc
effici
use
synthet
semisynthet
process
unlik
switch
plantbas
product
would
benefici
even
practic
howev
protein
also
use
antivir
includ
carbohydratebind
protein
lectin
plant
lectin
known
bind
inactiv
broad
rang
virus
block
glycan
structur
present
viru
surfac
exampl
griffithsin
lectin
produc
red
alga
genu
griffithsia
act
entri
inhibitor
multipl
virus
vaccin
current
avail
includ
hiv
zair
ebolaviru
coronavirus
respons
origin
sar
outbreak
sarscov
subsequ
outbreak
middl
east
respiratori
syndrom
merscov
griffithsin
potent
activ
virus
low
toxic
toward
human
cell
offer
broad
effect
therapeut
window
yet
clear
whether
griffithsin
inactiv
surfaceexpos
protein
sarscov
highli
conserv
conserv
uniqu
glycan
posit
crossreact
therefor
like
similarli
scytovirin
lectin
cyanobacterium
scytonema
varium
also
activ
multipl
virus
includ
hiv
zair
ebolaviru
marburg
viru
sarscov
studi
addit
plant
lectin
reveal
candid
show
activ
sarscov
ec
valu
middl
nanomolar
rang
toxic
concentr
mannosebind
lectin
typic
show
strongest
activ
sarscov
suggest
highmannos
glycan
might
effect
target
howev
lectin
specif
galactos
nacetylgalactosamin
glucos
nacetylglucosamin
also
show
antivir
effect
although
ec
valu
vari
greater
rang
interestingli
lectin
appear
target
two
differ
stage
viral
replic
cycl
indic
builtin
mechan
prevent
escap
mutant
plant
use
produc
rang
antivir
lectin
includ
griffithsin
cyanovirinn
cyanovirinn
fusion
protein
well
transgen
rice
line
express
griffithsin
cyanovirinn
simultan
seed
without
antibodi
transient
express
plant
would
provid
rapid
access
antivir
protein
process
scale
provid
gram
amount
within
week
transgen
plant
could
use
provid
perman
resourc
even
largerscal
product
transient
express
plant
excel
platform
provid
diagnost
protein
vaccin
candid
antivir
protein
respons
emerg
pathogen
wherea
diagnost
protein
viral
antigen
virusspecif
antibodi
use
immedi
compon
assay
kit
follow
evalu
approv
develop
pipelin
vaccin
therapeut
much
longer
due
need
preclin
clinic
test
moreov
pharmaceut
protein
must
produc
gmp
condit
ad
develop
time
cost
even
transient
express
plant
faster
tradit
platform
base
microb
mammalian
cell
requir
establish
stabl
cell
line
produc
final
product
need
develop
scaledup
process
scalabl
transient
express
system
hardwir
requir
cultiv
plant
transient
express
therefor
allow
provis
materi
clinic
test
within
week
largescal
product
clinicalgrad
materi
feasibl
minim
invest
uniqu
challeng
need
univers
test
entir
human
popul
unpreced
term
demand
world
need
go
zero
product
make
avail
multipl
billion
test
develop
develop
countri
set
transgen
plant
could
provid
solut
tobacco
legum
cereal
plant
grown
mani
environ
journal
preproof
product
antigen
antibodi
antivir
could
therefor
produc
use
local
infrastructur
distribut
network
alreadi
exist
food
case
cereal
seed
without
need
cold
chain
approach
establish
eu
pharmaplanta
project
humanitarian
applic
context
hiv
prophylaxi
could
facilit
inevit
rollout
test
sector
global
popul
pharmaplanta
project
also
examin
regulatori
aspect
molecular
farm
intern
boundari
similar
principl
could
appli
molecular
farm
commun
extrem
activ
establish
plantbas
process
product
diagnost
therapeut
protein
fight
two
current
eu
consortia
focus
molecular
farm
propos
divert
effort
help
product
protein
two
major
project
pharmafactori
http
pharmafactoryorg
newcotiana
http
newcotianaorg
develop
plantbas
platform
industri
applic
cooper
compani
manufactur
diagnost
kit
therapeut
product
crucial
move
product
along
pipelin
toward
commerci
opportun
help
address
current
pandem
also
creat
model
allow
rapid
target
respons
futur
pandem
glossari
angiotensin
convert
enzym
enzym
project
surfac
certain
human
cell
includ
pulmonari
epitheli
cell
appear
major
receptor
antibodydepend
cellmedi
cytotox
adcc
process
cell
immun
system
activ
lyse
target
cell
whose
surfac
antigen
bound
specif
antibodi
attenu
vaccin
live
vaccin
passag
multipl
time
reduc
virul
retain
antigen
properti
aggress
origin
strain
complex
glycan
oligosaccharid
molecul
contain
divers
sugar
residu
form
extens
highmannos
glycan
golgi
bodi
diseas
caus
coronaviru
group
relat
virus
infect
mammal
bird
tend
caus
respiratori
tract
infect
human
crosspresent
abil
antigenpres
cell
take
process
present
extracellular
antigen
mhc
class
molecul
cell
elisa
enzymelink
immunosorb
assayan
assay
format
immobil
target
protein
detect
antibodi
either
carri
label
direct
detect
turn
detect
anoth
antibodi
carri
label
gmp
good
manufactur
practiceth
set
regul
govern
product
approv
pharmaceut
product
highmannos
glycan
mannoserich
oligosaccharid
molecul
termin
mannos
residu
form
glycan
attach
protein
secretori
pathway
primarili
reach
golgi
bodi
hybridoma
cell
line
creat
fuse
antibodysecret
bcell
immort
myeloma
cell
line
result
hybrid
cell
immort
secret
singl
form
antibodi
monoclon
inactiv
vaccin
vaccin
base
live
pathogen
kill
inactiv
heat
chemic
treatment
lectin
plantderiv
protein
bind
carbohydr
molecular
farm
use
plant
product
protein
usual
extract
purifi
least
use
part
crude
extract
rather
fulfil
function
within
plant
neutral
antibodi
antibodi
interrupt
life
cyclerepl
cycl
pathogen
eg
prevent
interact
receptor
passiv
immunotherapi
administr
antibodi
target
particular
pathogen
molecul
rather
administr
antigen
caus
bodi
gener
antibodi
target
primeboost
vaccin
strategi
initi
prime
dose
must
complement
one
subsequ
booster
dose
order
elicit
strong
immun
respons
primer
short
oligonucleotid
anneal
dna
rna
templat
use
initi
dna
synthesi
pcr
rtpcr
experi
rtpcr
revers
transcriptas
polymeras
chain
reactiona
method
use
detect
case
quantifi
rna
first
revers
transcrib
cdna
amplifi
latter
pcr
subunit
expos
ntermin
subunit
spike
protein
proteolyt
releas
fullsiz
spike
protein
assembl
viral
particl
novel
coronaviru
respons
current
pandem
diseas
spike
protein
protein
protein
project
surfac
viru
particl
subunit
vaccin
vaccin
base
singl
polypeptid
deriv
pathogen
transient
express
express
strategi
plant
infiltr
agrobacterium
tumefacien
carri
express
construct
tdna
mani
cell
initi
transfect
tdna
stabli
transform
gene
carri
episom
tdna
express
short
time
day
degrad
vlp
viruslik
particlea
structur
ident
near
ident
viru
lack
origin
genom
render
unabl
replic
vlp
base
plant
virus
produc
express
capsid
protein
plant
abil
assembl
viru
particl
mani
speci
depend
protein
nucleic
acid
molecular
farm
commun
address
previou
epidem
pandem
scale
challeng
never
great
meet
demand
unpreced
test
one
major
aspect
challeng
need
organ
intern
respons
within
matter
month
even
week
coronaviru
outbreak
recur
need
ensur
infrastructur
remain
place
molecular
farm
commun
meet
futur
pandem
molecular
farm
commun
must
team
clinician
diagnost
pharmaceut
compani
ensur
translat
plantbas
protein
product
commerci
diagnost
kit
therapeut
current
molecular
farm
strategi
mitig
focu
transient
express
system
subsequ
transgen
crop
grown
contain
current
regul
adequ
cover
use
order
address
futur
pandem
necessari
reevalu
gmo
regul
particularli
europ
stifl
develop
benefici
technolog
